Literature DB >> 25040130

Reforming medicare's dialysis payment policies: implications for patients with secondary hyperparathyroidism.

Charu Gupta1, Glenn M Chertow, Mark T Linthicum, Karen Van Nuys, Vasily Belozeroff, Darryl Quarles, Darius N Lakdawalla.   

Abstract

OBJECTIVE: To demonstrate how expanding services covered by a "bundled payment" can also expand variation in the costs of treating patients under the bundle, using the Medicare dialysis program as an example. DATA SOURCES/STUDY
SETTING: Observational claims-based study of 197,332 Medicare hemodialysis beneficiaries enrolled for at least one quarter during 2006-2008. STUDY
DESIGN: We estimated how resource utilization (all health services, dialysis-related services, and medications) changes with intensity of secondary hyperparathyroidism (sHPT) treatment. DATA EXTRACTION
METHODS: Using Medicare claims, a patient-quarter level dataset was constructed, including a measure of sHPT treatment intensity. PRINCIPAL
FINDINGS: Under the existing, narrow dialysis bundle, utilization of covered services is relatively constant across treatment intensity groups; under a broader bundle, it rises more rapidly with treatment intensity.
CONCLUSIONS: The broader Medicare dialysis bundle reimburses providers uniformly, even though patients treated more intensively for sHPT cost more to treat. Absent any payment adjustments or efforts to ensure quality, this flat payment schedule may encourage providers to avoid high-intensity patients or reduce their treatment intensity. The first incentive harms efficiency. The second may improve or worsen efficiency, depending on whether it reduces appropriate or inappropriate treatment. © Health Research and Educational Trust.

Entities:  

Keywords:  Bundled reimbursement; Medicare; dialysis; end-stage renal disease; secondary hyperparathyroidism

Mesh:

Year:  2014        PMID: 25040130      PMCID: PMC4254132          DOI: 10.1111/1475-6773.12202

Source DB:  PubMed          Journal:  Health Serv Res        ISSN: 0017-9124            Impact factor:   3.402


  21 in total

1.  K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease.

Authors: 
Journal:  Am J Kidney Dis       Date:  2003-10       Impact factor: 8.860

2.  Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis.

Authors:  Glenn M Chertow; Geoffrey A Block; Ricardo Correa-Rotter; Tilman B Drüeke; Jürgen Floege; William G Goodman; Charles A Herzog; Yumi Kubo; Gerard M London; Kenneth W Mahaffey; T Christian H Mix; Sharon M Moe; Marie-Louise Trotman; David C Wheeler; Patrick S Parfrey
Journal:  N Engl J Med       Date:  2012-11-03       Impact factor: 91.245

3.  Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy.

Authors:  Adrian Fine; James Zacharias
Journal:  Kidney Int       Date:  2002-06       Impact factor: 10.612

4.  Medicare program; end-stage renal disease prospective payment system. Final rule.

Authors: 
Journal:  Fed Regist       Date:  2010-08-12

5.  Association of secondary hyperparathyroidism with CKD progression, health care costs and survival in diabetic predialysis CKD patients.

Authors:  Glen T Schumock; Dennis L Andress; Steven E Marx; Raimund Sterz; Amie T Joyce; Kamyar Kalantar-Zadeh
Journal:  Nephron Clin Pract       Date:  2009-07-10

6.  Health policy basics: Medicaid expansion.

Authors:  Ryan A Crowley; William Golden
Journal:  Ann Intern Med       Date:  2014-03-18       Impact factor: 25.391

7.  Economic burden of cardiovascular events and fractures among patients with end-stage renal disease.

Authors:  Quan V Doan; Michelle Gleeson; John Kim; Rohit Borker; Robert Griffiths; Robert W Dubois
Journal:  Curr Med Res Opin       Date:  2007-07       Impact factor: 2.580

8.  Parathyroidectomy versus cinacalcet hydrochloride-based medical therapy in the management of hyperparathyroidism in ESRD: a cost utility analysis.

Authors:  Rajeev Narayan; Robert M Perkins; Elizabeth P Berbano; Christina M Yuan; Robert T Neff; Eric S Sawyers; Fred E Yeo; Gwenaelle M Vidal-Trecan; Kevin C Abbott
Journal:  Am J Kidney Dis       Date:  2007-06       Impact factor: 8.860

9.  Racial Segregation and the American Foreclosure Crisis.

Authors:  Jacob S Rugh; Douglas S Massey
Journal:  Am Sociol Rev       Date:  2010-10-01

Review 10.  Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment.

Authors:  Melanie S Joy; Paul C Karagiannis; Fred W Peyerl
Journal:  J Manag Care Pharm       Date:  2007-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.